Your browser doesn't support javascript.
loading
Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002.
Meyers, Gabrielle; Hamadani, Mehdi; Martens, Michael; Ali, Haris; Chevallier, Patrice; Choe, Hannah; Harris, Andrew C; Holler, Ernst; van Hooren, Eric; Klaassen, Willem; Leifer, Eric; van Oosterhout, Ypke; Perez, Lia; Pusic, Iskra; Stelljes, Matthias; van der Velden, Walter; Ammatuna, Emanuele; Beauvais, David; Cornillon, Jérôme; Maziarz, Richard T; Schetelig, Johannes; Romeril, Jennifer; MacMillan, Margaret L; Levine, John E; Socié, Gérard.
Afiliación
  • Meyers G; Center for Hematologic Malignancies, Oregon Health and Science University, Knight Cancer Institute, Portland, OR, USA. meyersg@ohsu.edu.
  • Hamadani M; BMT & Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin and Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Martens M; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, and Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Ali H; Division of Leukemia, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical, Duarte, CA, USA.
  • Chevallier P; Centre Hospitalier Universitaire de Nantes, Nantes, France.
  • Choe H; Division of Hematology, The Ohio State University Comprehensive Cancer Center - The James, Columbus, OH, USA.
  • Harris AC; MSK Kids Stem Cell Transplantation and Cellular Therapies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Holler E; Universitätsklinikum Regensburg, Regensburg, Germany.
  • van Hooren E; Xenikos BV, Nijmegen, The Netherlands.
  • Klaassen W; Xenikos BV, Nijmegen, The Netherlands.
  • Leifer E; National Heart, Lung, and Blood Institute, Bethesda, MD, USA.
  • van Oosterhout Y; Xenikos BV, Nijmegen, The Netherlands.
  • Perez L; H. Lee Moffitt Cancer Center, Tampa, FL, USA.
  • Pusic I; Division of Oncology, BMT and Leukemia Section, Washington University School of Medicine, St. Louis, MO, USA.
  • Stelljes M; Universitätsklinikum Münster (UKM), Münster, Germany.
  • van der Velden W; Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Ammatuna E; Universitair Medisch Centrum Groningen, Groningen, The Netherlands.
  • Beauvais D; Hematology Department, CHU Lille, Lille, France.
  • Cornillon J; Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France.
  • Maziarz RT; Center for Hematologic Malignancies, Oregon Health and Science University, Knight Cancer Institute, Portland, OR, USA.
  • Schetelig J; Universitaetsklinikum Carl Gustav Carus Dresden, Dresden, Germany.
  • Romeril J; The Emmes Company, Rockville, MD, USA.
  • MacMillan ML; Blood and Marrow Transplantation & Cellular Therapy Program, Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
  • Levine JE; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Socié G; Hematology Transplantation, Hospital St Louis and University Paris Cité, Paris, France.
Bone Marrow Transplant ; 58(12): 1416-1418, 2023 12.
Article en En | MEDLINE | ID: mdl-37749187
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Inmunoconjugados / Enfermedad Injerto contra Huésped Límite: Humans Idioma: En Revista: Bone Marrow Transplant Asunto de la revista: TRANSPLANTE Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Inmunoconjugados / Enfermedad Injerto contra Huésped Límite: Humans Idioma: En Revista: Bone Marrow Transplant Asunto de la revista: TRANSPLANTE Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos